Menu Close

Tag: 2019 News

Court Rules “On-Call” Scheduling Requires 2 Hours Pay

A California Court of Appeal just made a sweeping change in California’s reporting time pay rules which now limits a common “on-call” scheduling practice used by employers throughout the state.

In 2012, Skylar Ward worked as a sales clerk in a Tilly’s, Inc., store in Torrance, California.

Under Tilly’s scheduling policy, Ward was required to call in approximately two hours before the start of her shift to determine whether she needed to come to work. If Tilly’s told her to report to work, she was required to do so and would be paid for that shift as normal. However, if Tilly’s informed her that there was no need to come in, Ms. Ward would receive no compensation.

Ward filed a putative class action complaint in 2015. The trial court sustained a demurrer without leave to amend, finding that by merely calling in to learn whether an employee will work a call-in shift, Ward and other employees do not report to work as contemplated by Wage Order 7. The court of appeal reversed in the published case of Ward v. Tilly’s, Inc.

The court held that merely calling in for one of these mandatory on-call shifts constitutes “report[ing] to work,” which entitled Ms. Ward and her coworkers to a minimum of two hours of reporting time pay under the applicable wage order.

Prior to the case, various courts had disagreed about what it truly meant to “report to work” within the context of this provision, with many courts – not to mention employers – understandably believing that this required the employee to physically report to the workplace location in order to be eligible for reporting time pay.

In relevant part, the court examined the language from the reporting time rule contained within Wage Order No. 7-2001 codified at California Code of Regulations, title 8, section 11070.

The court ultimately reasoned that even having to place a telephone call as part of a mandatory on-call schedule fell within this “reporting” rule for two main reasons. First, requiring reporting time pay would “require employers to internalize some of the costs of overscheduling, thus encouraging employers to accurately project their labor needs and to schedule accordingly.”

Second, it would also “compensate employees for the inconvenience and expense associated with making themselves available to work on-call shifts, including forgoing other employment, hiring caregivers for children or elders, and traveling to a worksite. In relying on these public policy considerations, the court aligned itself with prior California cases that tended to tie the compensability of worktime to the degree of employer control over an employee’s activities.

The court left several key questions unanswered. Most notably, the court failed to address the issue of whether its holding would apply retroactively – potentially exposing countless employers across the state that utilize similar on-call scheduling policies to staggering class action liability.

The court also neglected to address the inherent line-drawing problem contained within its decision; that is, how long before a shift could an employee call in and still have it constitute compensable reporting? If not two hours, then how long?

Small Pharmacies Sue Major PBM for “Secret Rebates”

Independent pharmacists across Ventura County have filed a lawsuit against OptumRx, alleging the company manipulated drug pricing to enable lower reimbursement rates paid to small drugstores and plunging businesses underwater.

OptumRx, one of the biggest operations of its kind in the United States and part of the UnitedHealth network, sets payment rates as the pharmacy benefit manager for the Gold Coast Health Plan. The publicly funded Gold Coast organization provides Medi-Cal insurance to nearly 200,000 low-income Ventura County residents.

The pharmacists allege the company used contracts negotiated with agents of pharmacies to force the businesses into accepting payment that often fell below costs. OptumRx threatened people who pushed back with expulsion from the network, the complaint stated.

The lawsuit alleges unfair trade practices, breach of contract and violation of California law. It was filed by 18 companies and individuals in Ventura County Superior Court.

The litigation also targets three pharmacy services administration organizations – operated by Cardinal Health, Arete Pharmacy Network and AmerisourceBergen – that worked as middlemen between the pharmacies and OptumRx.

Leaders of OptumRx have repeatedly defended their pricing in a drama that dates back to last summer, shortly after the company assumed its role as Gold Coast’s pharmacy benefit manager.

“OptumRx’s role is to ensure consumers and health plan payers have convenient access to affordable prescription medications, and we will continue to work to help lower health care costs for Gold Coast Health Plan and California taxpayers,” said OptumRx spokesman Drew Krejci in a statement Thursday. “We believe this lawsuit is without merit and will vigorously defend ourselves.”

Pharmacists have crowded meetings of the Ventura County Medi-Cal Managed Care Commission for months, complaining about below-market rates they say shut down the Medical Plaza Pharmacy in Fillmore and put many others in jeopardy. The commission governs Gold Coast.

An independent consultant reviewed the rates and told the commission in April that the reimbursement paid by OptumRx is comparable to payment in similar Medicaid plans in California and elsewhere. After a closed-door discussion, commissioners announced they would not try to force the pharmacy benefit manager to raise the rates.

The lawsuit alleges OptumRx won the Gold Coast contract because it offered price guarantees and met the guarantees by obtaining secret rebates from drug makers and then manipulating pricing.

OptumRx also used something called the “maximum allowable cost” list to force reimbursement down, pharmacists claim. The so-called MAC list helps set the reimbursement rate and is supposed to be influenced by prices different distributors ask for the same generic medication. The pharmacists allege OptumRx ignored market prices and made up its own maximum allowable cost “based on thin air.”

It is “a moving target moved at Optum’s whim,” the lawsuit stated. It alleged OptumRx also kept its MAC price for generic drugs secret and violated state law by not making decisions on appeals by pharmacists within seven business days.

Bay Area Doctor Arrested for SDI Fraud Schemes

A federal grand jury indicted Dr. George David, a Freemont Psychiatrist, and Linda Nguyen with conspiracy to commit mail fraud and substantive mail fraud.

According to the indictment filed January 29, 2019, and unsealed in February, David, 78, and Nguyen, 66, of Union City, engaged in a scheme to defraud California’s State Disability Insurance (SDI) program.

The SDI program is designed to provide partial wage replacement benefits to eligible California workers who are unable to work due to a non-work-related illness, injury, or pregnancy.

To receive SDI benefits, a claimant must file a claim for benefits supported by a Physician/Practitioner Certification attesting to the claimant’s disability.

According to the indictment, David provided fraudulent Physician/Practitioner Certifications to support fraudulent SDI applications for non-disabled claimants. In addition, the indictment alleges that Nguyen facilitated the fraud by assisting non-disabled persons with the execution and submission of fraudulent documents.

The indictment further alleges that Nguyen charged the non-disabled persons for processing their fraudulent applications. In sum, the defendants each were charged with one count of conspiracy to commit mail fraud, in violation of 18 U.S.C. § 1349, and one count of substantive mail fraud, in violation of 18 U.S.C. § 1341.

The defendants were arrested and made their initial appearances before U.S. Magistrate Judge Donna M. Ryu. Both defendants were released on bond. Magistrate Judge Ryu scheduled David’s and Nguyen’s next appearances for February 8 and February 15, 2019, respectively, for arraignment and identification of counsel.

If found guilty, the defendants face a maximum statutory sentence of 20 years in prison for each count in the indictment. However, any sentence following conviction would be imposed by the court after consideration of the U.S. Sentencing Guidelines and the federal statute governing the imposition of a sentence, 18 U.S.C. § 3553.

Special Assistant U.S. Attorney Christopher Vieira is prosecuting the case with the assistance of Kimberly Richardson. The prosecution is the result of an investigation by the FBI and Social Security Administration Office of the Inspector General.

TV Ads to Include Drug Price Transparency

Johnson & Johnson said on Thursday it will start adding the price of its medicines to television commercials by next month, becoming the first drugmaker to heed a call by U.S. President Donald Trump for price transparency of drugs advertised directly to consumers on TV.

The healthcare conglomerate said it will include both the list price of a product – the price before any rebates or discounts to insurers or pharmacy benefit managers – as well as potential out-of-pocket costs that patients will pay.

The move, announced in a statement on J&J’s website, won swift praise from U.S. Health and Human Services Secretary Alex Azar. Last May, Azar’s office released a blueprint for reducing the cost of drug prices, which included a proposal to require disclosure of list prices in TV ads for drugs.

“We commend Johnson & Johnson for recognizing the value of informing consumers about list prices and for doing so voluntarily. We call on other manufacturers to follow their lead,” Azar said in a statement.

Trump made lowering the cost of prescription drugs for U.S. consumers a central issue of the 2016 presidential campaign and emphasized it again in his State of the Union Address this week.

Ads for the blood thinner Xarelto, J&J’s most widely prescribed medicine, will be the first television spot to include pricing information, the company said. The treatment used to prevent blood clots costs about $450 to $540 a month.

Congress has increased its scrutiny of U.S. drug pricing since Democrats took over control of the House of Representatives in January, while pressure is also coming from the Republican-led Senate.

Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of the committee, on Monday invited executives from seven pharmaceutical companies, including J&J, to testify at a Feb. 26 hearing on rising drug prices.

Corvel Reports on 10,000 Telehealth Visits

As the first company to offer telehealth in the workers’ compensation space, there was no roadmap to follow. Since adding telehealth services in 2015, CorVel has now completed 10,000 virtual visits. With this significant milestone, David Lupinsky, CorVel’s Vice President of Medical Review Services reported on a few of the lessons the company learned:

In order to make telehealth equally efficacious to the brick and mortar visit, it needed to offer the same features patients have come to expect, value, and appreciate. Immediate access to medical services such as physical therapy, diagnostics imaging, pharmacotherapy, and durable medical equipment are essential to a successful telehealth offering.

Telehealth physicians have prescribed medications, ordered vaccines, requested durable medical equipment, and scheduled short term physical therapy and diagnostic imaging when clinically appropriate.

Brick and mortar evaluations take 4+ hours on average, factoring travel and wait times, while virtual visits last an average 30 minutes from start to finish. And though it is customary for injured employees to wait 1-2 days for the claim to be completely set up before receiving treatment, telehealth provides appropriate clinical care within minutes of the injury. Moreover, all claims data obtained through virtual visits is loaded into CareMC, its claims management technology, making the information immediately and easily accessible for all constituents.

Interdisciplinary care is defined by its multi-specialty shared relationships and common goals. While it’s appropriate to have multiple team members and providers working on a claim, CorVel has learned the importance of working towards a shared goal of providing timely, appropriate care for injured workers.

To ensure consistent protocols and concordance with each case, it has a dedicated medical director who oversees telehealth physicians and maintains communication with the nursing director. Communication between the claims intake department (FNOL), triage nurse, and treating telehealth physician significantly reduces duplication of services and thus patient wait times, patient frustration, and coding errors.

As a result of an integrated and shared database, all data captured by its 24/7 nurse triage and telehealth services can be accessed by both its FNOL intake team and our adjusters in real time. This is crucial to minimizing talk time, ensuring consistency, and maximizing the patient experience.

With telehealth becoming more popular in “mainstream healthcare”, it is now an expectation for injured employees. Since patients expect a telehealth platform to provide these services, it’s essential they be delivered in a coordinated fashion with updated clinical notes available to the providers on follow up visits to maintain an equal or superior standard of care to brick and mortar outcomes.

Healthcare is evolving and at the core of its change is data and artificial intelligence (AI). At CorVel, it has utilized AI with the Edge, its completely modernized claims management portal. The Edge takes claims data from a variety of sources, including bill review and pharmacy, to identify potential risk for certain claims and push out telehealth visits to mitigate the risk.

The real cost of a “minor” injury can significantly change when viewed in the context of medications, psychosocial factors, testing, and opioids. Automatic identification of these proprietary factors can elevate this case to higher acuity and a telehealth visit can be pushed out to the patient for a collaborative and holistic approach to care that can be implemented while working in tandem with other treating physician already involved in the patient’s care.

Being able to integrate this data into its claims management platform has allowed CorVel to prevent many minor injuries from becoming expensive claims. Read Corvel’s recent white paper, Breaking Down Barriers, to learn more about its approach to telehealth in performance-based networks.

Novartis and Eli Lily Support end to PBM Rebates

Last week the Department of Health and Human Services proposed a rule to end the industry-wide system of after-market discounts called rebates that pharmacy benefit managers (PBMs) receive from drugmakers, a practice that has been under increased scrutiny.

If finalized, the rule would change a system that has been in place for decades and that has been criticized for obfuscating the real price of prescription medicines.

Now CEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health system, who have inflated the costs of their medicines. Novartis’ Vas Narasimhan, and Eli Lilly’s David Ricks backed the proposals to end rebates paid to pharmacy benefit managers and health insurers that push up the prices of their diabetes medicines.

While the justification for the rebates is that they pay for improvements elsewhere in the US healthcare system, big pharma companies argue they don’t benefit as they have to push up prices to maintain profit margins. Critics also say that patients do not benefit either, as in the US they may have to cover part or all of their medicine costs, depending on their health insurance arrangements.

The administration of president Donald Trump in January proposed a rule that would end the rebate system, or pass savings to patients.

In an interview with Reuters, Novartis said it pays almost 50% of gross revenues in the US into rebates. The Novartis CEO added: “If you return those rebates to patients, so patients pay less out of pocket, I think that is something that makes a lot of sense and will correct a distortion in the marketplace.”

But he also said efforts to link US prices to those in other countries are “destructive”, adding that in some cases US prices are cheaper.

“There are situations where prices in the US are certainly higher than the prices in Europe, but there are many situations, as well, where they are very comparable,” he said. “It’s difficult to make blanket statements, like this is always happening.”

Eli Lilly’s chief executive David Ricks, in a quarterly conference call with analysts, said the proposals are a “win for patients, lowering their out-of-pocket costs at the pharmacy with the greatest benefit realized by patients taking more highly-rebated products such as insulin.”

Rival diabetes drug manufacturers Sanofi and Novo Nordisk have also backed the proposals to cut rebates.

Carriers Sued for QME Sexual Misconduct

The San Francisco Chronicle reports that three women who say they were sexually assaulted by an Oakland doctor who reviewed their cases for workers’ compensation claims have sued the state of California and several insurance providers, alleging the agencies were aware of the doctor’s abuse and continued sending patients to him anyway.

The women, who are not identified in the complaint, were required to see Dr. John Warbritton after being injured while at work and filing for workers’ compensation with the state. They each said they reported the alleged abuse by Warbritton and were told they would have to continue seeing him for their claims to proceed.

Warbritton was a QME, and an orthopedic specialist in the East Bay since 1982 but lost his medical license in April 2017, after two of the women accused him of sexual misconduct. Warbritton voluntarily gave up his license.

At the time, Warbritton’s license was already suspended because of charges filed against him in 2016 for transporting child pornography images on his phone and a laptop while flying from Thailand to San Francisco. Warbritton pleaded guilty to the child pornography charges and was sentenced to seven years in prison in September 2018.

The new complaint, filed Jan. 22 in Alameda County Superior Court, alleges that Warbritton’s history of abuse toward female patients was so well known that the agencies that worked with him should be held accountable. The complaint is filed as a class action, and attorney Waukeen McCoy said he expects more women to join the case as it becomes public.

Three insurance providers also are named as defendants: Travelers Indemnity Company in Hartford, Conn.; JT2 Integrated Resources in Oakland; and York Risk Services Group in Jersey City, N.J. Officials from those companies did not respond to requests for comment on the complaint.

Warbritton was suspended as a QME in February 2018, 10 months after he lost his medical license and while the child pornography charges were under investigation.

All of the women said they reported being molested by Warbritton to their lawyers, and in some cases to other doctors treating them and to the insurance providers. One woman said in an interview that her attorney had heard similar complaints about Warbritton before.

In the complaint, the women describe multiple incidents of inappropriate language and touching. All of the women said he touched them on the breast, thigh or between the legs in an inappropriate way. They say Warbritton made comments about their bodies and their undergarments. They say he talked about his sex life and made references to having sex with employees when they were underage.

MTUS/ACOEM Guidelines Now Free and Online

The Division of Workers’ Compensation announced that medical providers who treat injured California workers can now have free online access to the State’s Medical Treatment Utilization Schedule (MTUS) guidelines.

“Medical providers in California should ensure that treatment decisions for injured workers are based on the best available evidence,” said George Parisotto, DWC Administrative Director. “By providing these guidelines free of charge, we are removing barriers that we expect will improve quality of care and reduce friction in the utilization review process.”

Licensed healthcare providers who treat California injured workers can use MDGuidelines: CA MTUS-ACOEM Edition to quickly search the latest evidence-based recommendations incorporated into the State’s MTUS. Providers who perform qualified medical evaluations, utilization review or independent medical review can also register to use the online tool free of charge.

The MTUS, a set of regulations based on the principles of evidence-based medicine, has adopted treatment guidelines developed by the American College of Occupational and Environmental Medicine (ACOEM). In most cases, medical treatment that is reasonable and necessary to cure or relieve an injured worker from the effects of injury means treatment that is based upon the ACOEM treatment guidelines. Providers must register in order to gain access to the site administered by the Reed Group. The site includes online training webinars and instructions. Users can email MTUS@reedgroup.com for more information.

The Division of Workers’ Compensation monitors the administration of workers’ compensation claims, and provides administrative and judicial services to assist in resolving disputes that arise in connection with claims for workers’ compensation benefits.

SCOTUS Affirms Employers Arbitration Rights

In a unanimous opinion decided this January, the United States Supreme Court continued its expansive reading of the Federal Arbitration Act and arbitration provisions, rebuffing an effort by some to erect an additional hurdle that would interfere with an employers’ ability to enforce arbitration agreements. The case is Henry Schein Inc. v. Archer and White Sales Inc.

By rejecting the “wholly groundless” exception that courts had used to “spot-check” whether a claim of arbitrability was plausible before compelling arbitration, all lower federal courts must now compel arbitration in all cases where the parties have agreed to delegate the issue of “who decides what is arbitrable” to an arbitrator.

The Court’s decision – the first authored by Justice Brett Kavanaugh – extinguishes a conflict among various circuit courts of appeal and provides uniform guidance to employers who use arbitration agreements throughout the country. Employers should familiarize themselves with the ruling in order to ensure that their dispute resolution plans are fully compliant and in line with this decision.

In keeping with its recent interest in defining the contours of the FAA, the Court accepted the case to clear up the conflict among the circuit courts. A unanimous Court reiterated that it meant what it said in the 2009 Rent-A-Center, West Inc. v Jackson case and that the parties are certainly free to delegate issues of arbitrability to an arbitrator: “The FAA does not contain a ‘wholly groundless’ exception, and we are not at liberty to rewrite the statute passed by Congress and signed by the President.” The Court went further and confirmed it saw no reason to “engraft our own exceptions onto the statutory text.”

There’s a double dose of good news for employers in the Henry Schein ruling. First off, the decision clears up conflicting case law in the various circuits, and employers now know there is a uniform interpretation as to the enforceability of parties’ delegations of arbitrability to an arbitrator. Second, the decision sweeps aside a possible hurdle that might have otherwise existed in trying to enforce an arbitration agreement with employees.

However, liberal legislators are very unhappy with the broad rights to arbitrate agreements. Congress has once again proposed legislation that would seek to ban mandatory workplace arbitration of employment claims, despite a string of United States Supreme Court decisions upholding arbitration and class/collective action waivers as a lawful and appropriate mechanism to resolve workplace disputes.

H.R. 7109, the Restoring Justice for Workers Act, was introduced by Representative Jerrold Nadler, D-N.Y., and Representative Bobby Scott, D-Va., with 58 Democratic co-sponsors. Similar legislation is expected to be introduced in the Senate by Senator Patty Murray, D-Wash, with eight Democratic co-sponsors. The proposed legislation would overturn the U.S. Supreme Court’s decision in Epic Systems, and would amend the National Labor Relations Act to specifically prohibit class and collective action waivers under a new “Section 8(a)(6).”

Study Shows No Value to Topical Compounded Pain Creams

Decisions made by UR physicians are justified by evidence based medicine, which is derived from scientific medical studies.  A new study will help rule out compounded pain creams in most cases.

The new study reported by Reuters Health and published in the Annals of Internal Medicine suggests that compounded pain creams are no better for chronic pain than topical treatments that contain no medicine at all..The current study focused on pain creams made from medicines that are often prescribed for pain in pill form such as muscle relaxants, anticonvulsants and non-steroidal anti-inflammatory (NSAID) drugs.

In this study, researchers randomly assigned 399 patients with different types of chronic pain to receive either a compounded cream containing an analgesic or a placebo cream without any medicine.

After one month, 36 percent of patients who used pain creams and 28 percent who got placebo creams reported less pain than they had at the start, a difference that was too small to rule out the possibility that it was due to chance.

“We know from other studies that some of the agents (lidocaine, non-steroidal anti-inflammatory drugs) may be effective for certain types of acute and chronic pain, so it is surprising that the difference here did not reach statistical significance in any of the pain types,” said senior study author Dr. Steven Cohen, a pain researcher at Walter Reed National Military Medical Center in Bethesda, Maryland, and Johns Hopkins Medicine in Baltimore.

“This matters because compounded pain creams are much more expensive than prescribed (lidocaine, diclofenac) or over-the-counter (capsaicin) pain creams, but they didn’t provide meaningful benefit compared to placebo cream,” Cohen said by email.

All of the patients in the current study were treated at pain clinics at Walter Reed and had one of three types of pain syndromes. Within these three groups, patients were randomly chosen to receive either a compounded cream or a placebo cream.

One third of the patients had neuropathic pain, which happens due to nerve damage and includes phantom limb pain experienced by amputees. Patients in this group who got compounded creams received anticonvulsants.

Another third had so-called nociceptive pain, the most common kind that is often due to an injury or infection, not nerve damage. Patients in this group who got compounded creams received muscle relaxants and NSAIDs.

And one third had “mixed” pain caused by a variety of things; many of the compounded creams were similar to drugs provided for nerve damage or nociceptive pain.

When patients rated their pain levels on a 10-point scale, with 10 being the most painful, the average pain reductions reported by both compounded-cream users and the placebo group after a month were nearly identical. The difference between groups was 0.1 points for neuropathic pain and 0.3 points for both nociceptive and mixed pain.